-
Eur Radiol: How does the size of the nodules found in lung CT screening affect the frequency of screening?
Time of Update: 2021-03-18
In summary, this study is the first to use semi-automatic software to segment the nodule volume on thin-layer LDCT to analyze the distribution of Lung-RADS v1.
The nodule volume obtained by semi-automatic software segmentation can stratify the LC risk of Lung-RADS v1.
-
Hands-on experience | Information-based assistance to hospital medical insurance cost management of 4 initiatives
Time of Update: 2021-03-11
Case provided: Chen Junqiang, Liang Bing, First Affiliated Hospital of Guangxi Medical University; Comment Experts: Lin Seoul, Wu Ming, Expert Committee on Capacity Building for Modern Hospital Manag
-
2020 Top 10 New Innovative Drugs Available Worldwide
Time of Update: 2021-03-11
Zhang Ze and Xin Mingyu in 2020, the global approval of innovative drugs in the state of blowout, including a number of heavy anti-tumor innovative drugs, including the cancer circle of LOXO-292 (Ret
-
Level 3 hospital classification management is coming!
Time of Update: 2021-03-11
The program proposes to guide and support the development of some municipal hospitals to research-oriented hospitals, adjust the assessment methods, establish a matching department and personnel management system and full performance appraisal and evaluation system, and gradually realize the new pattern of rational layout of medical institutions in the city, the continuity of various functional differentiation, the appropriate employment and the coordinated development.
-
Osaikang forced Hengrui to win 2 billion
Time of Update: 2021-03-10
Table 1: Currently reviewed tymoamine-related products Source: Minet MED2.0 China Drug Review Database Currently in the domestic market, tymoamine capsules and injections have been approved for listing, capsule evaluation enterprises Tianshili, Shuangli Pharmaceuticals, and has been included in the fourth batch of national collection catalog, will be the original study of Merca East to start a price war, and injections in addition to Hengrui Medicine, Osaikang also according to the new classification was approved as the same evaluation.
-
Science Sub-Paper: Develop nanoparticles that can cross the blood-brain barrier!
Time of Update: 2021-03-10
"In addition to demonstrating the usefulness of this new platform in delivering drugs to the brain, this paper is also the first systematic adjustment of surface chemical properties and coating densities to adjust the ability of nanoparticles to pass through tightly connected biological barriers," said Dr. Wen Li of the Department of Anesthesiology, Peri surgery and Pain Medicine at Bregan Women's Hospital, the lead author of the paper.
-
Focus on the JPM | Wanchun new whitening drug Punabrin III clinical up to the main...
Time of Update: 2021-03-10
Punabrin, with its unique mechanism of action, is able to quickly protect neutral granulocytes in the first 8 days, complementing G-CSF co-use time and significantly reducing the full-cycle severe CIN rate caused by chemotherapy in patients with non-myelin cancer.
-
FDA grants padeliporfin ImPACT fast...
Time of Update: 2021-03-10
Steba biotech focuses on the development of Padeliporfin ImPACT as an innovative oncology platform with the potential to provide surgical-like efficacy and retain organs in UTUC and other solid tumors.
-
2021 CDE Release: Circulars Nos. 1 and 2
Time of Update: 2021-03-10
On January 15, 2021 and January 18, 2021, respectively, the Drug Audit Center of the State Drug Administration issued Circular No. 1 of 2021 and No. 2 of 2021: 1. Notice of the Drug Review Center of
-
"China esophageal cancer radiation therapy guide" interpretation tour media conference held a grand
Time of Update: 2021-03-10
In his opening remarks, Professor Li Baosheng thanked Academician Yu Jinming for his strong support and guidance in the formulation and revision of the Guide, so that the Guide can embody the principles of norms, characteristics and practicality - both covering the relevant norms of comprehensive treatment and highlighting the clinical issues of concern in the diagnosis and treatment of esophageal cancer: such as target area drawing, dose optimization, quality control, etc.
-
PD-1/PD-L1 Characteristic Differences and Research...
Time of Update: 2021-03-10
inhibitors targeted at PD-1/PD-L1 showed significant therapeutic effects in clinical applications, and many PD-1/PD-L1 inhibitors were listed, but different PD-1/PD-L1 inhibitors varied in terms of antibody source, type, stability, specificity, affinity, adaptive evidence, dosage, immunogenicity, pharmacodynamics, etc.
-
Thyme Bio announced the granting of an exclusive license to Etana Dae-Yu in Indonesia
Time of Update: 2021-03-10
Since its launch, the original drug Beval pearl single anti-injection has been approved worldwide for the treatment of non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritometrial cancer and other solid tumors, its remarkable efficacy and good safety has been generally recognized.
-
Youzhiyou BioCD38xCD3 dual-specific antibody new drug has been approved clinically
Time of Update: 2021-03-10
China's State Drug Administration (NMPA) Drug Review Center (CDE) recently announced that Youzhiyou Biological research and development of "injection recombinant anti-CD38 and CD3 dual specific antibodies" (research and development code: Y150) to obtain a clinical trial implied license, the adaptive disease is multiple myeloma (MM).
-
WCLC's a heavy hit! PD-1/L1、RET、MET...... Hot...
Time of Update: 2021-03-10
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in PreviouslyTreated, The results of the KEYNOTE-010 study (NCT01905657), published at this meeting of PD-L1-Positive Advanced NSCLC, showed that Pablic pearl monoanti (2 or 10 mg/kg Q3W) significantly improved OS in patients with advanced NSCLC (PD-L1 TPS≥50% and ≥1%) who had previously received treatment.
-
A new combination therapy may help the immune system better attack cancer
Time of Update: 2021-03-10
Working in mice, a team led by Jamey Weichert, professor of radiology, and Zachary Morris, professor of human oncology, is combining two different techniques in its approach, using targeted radionuclide therapy, which delivers a low dose of cell-weakening radiation specifically to cancer cells, followed by immunotherapy, which helps the immune system to recognize and destroy cancer cells.
-
CXCL11 and CXCR3alt levels predict which bladder cancer patients are on...
Time of Update: 2021-03-10
the results of the study, published january 13, 2021 in the journal Science Translational Medicine, are titled "The Intratumoral CXCR3 Chemokine system is predictive of the response in human bladder cancer." author of the paper is Dr. Michael Schmück-Henneresse of the Schalette School of Medicine in Berlin.
-
"Pharmaceutical Speed Reading Society" central media bitterly approved surrogacy abandonment and another drug company Alzheimer's disease research...
Time of Update: 2021-03-10
clinical all subjects into the group of green leaf pharmaceutical company Boan bio-independent research and development of innovative antibody products for the treatment of new coronary pneumonia - LY-CovMab has completed phase I clinical trials in China all subjects into the group.
-
Cell: Reveals the antiviral immune response points of targeted tumors in triple-negative breast cancer...
Time of Update: 2021-03-10
'Our study reveals a new way to activate the body's inflammatory response by specifically targeting cancer cells,' said Dr. Elizabeth Bowling, .
-
Insights | Analysis of the development of biopharmaceutical industry in Yantai City
Time of Update: 2021-03-10
Sun Xiaoyang biomedical health industry is a national strategic emerging industry, but also known as "the sunrise industry that will never decline", in recent years, Yantai Municipal Government estab
-
Review of FDA's New Drug Approval Report 2018-2020
Time of Update: 2021-03-10
In particular, in its 2020 report, the FDA reported more new adaptations than in the previous two years combined, including major breakthroughs in certain diseases: 1) Benlysta: the first FDA-approved drug to treat lupus nephritis.
